KMID : 1197720150080020098
|
|
´ëÇÑÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸÁö 2015 Volume.8 No. 2 p.98 ~ p.102
|
|
Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson¡¯s Disease Dementia
|
|
Oh Yoon-Sang
Kim Joong-Seok Lee Phil-Hyu
|
|
Abstract
|
|
|
Objective: A recent study showed that rivastigmine and memantin improved behavioral and psychiatric symptoms of dementia (BPSD) in Alzheimer¡¯s dementia. Furthermore, according to recent guidelines presented by the Movement Disorder Society, rivastigmine is efficacious for the treatment of dementia in Parkinson¡¯s disease (PD). We investigated the efficacy of rivastigmine for BPSD in patients with Parkinson¡¯s disease dementia (PDD).
Methods: Twenty-three patients in whom cognitive impairment occurred at least one year after a diagnosis of PD participated in this open-label trial. Cognitive, psychiatric, and motor symptoms were assessed before and after 24 weeks of treatment with rivastigmine using unstructured clinical assessments and rating scales including the Unified Parkinson¡¯s Disease Rating Scale, Mini-Mental State Examination (MMSE), and the Neuropsychiatric Inventory.
Results: Age (¡¾ standard deviation) was 74.7 ¡¾ 5.9 years, average duration of PD was 3.5 ¡¾ 3.7 years, Hoehn and Yahr scores were 2.2 ¡¾ 0.8, and baseline MMSE scores were 19.1 ¡¾ 4.2. Improvements in global mental symptoms and neuropsychiatric symptoms were significant; among them, hallucination, depression and appetite changes improved. Caregiver distress significantly decreased, including distress resulting from hallucinations, depression, apathy, and appetite changes.
Conclusions: Although controlled trials are required, the findings suggest that rivastigmine is useful for control of several neuropsychiatric symptoms and beneficial for caregiver distress in patients with PDD.
|
|
KEYWORD
|
|
Parkinson disease, Dementia, Rivastigmine, Neuropsychiatry, Symptoms
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|